Literature DB >> 3930316

Production of monoclonal antibodies in culture.

S Reuveny, D Velez, F Riske, J D MacMillan, L Miller.   

Abstract

Factors that affected the production of monoclonal antibodies by a mouse-mouse hybridoma cell line, propagated in vitro in stirred vessels, were investigated. The purpose of the research was to estimate the efficiency of this system for large scale production of monoclonal antibodies. The antibody produced by these hybridoma cells was an IgG2a, specific for a surface antigen on Rhizobium japonicum NR-7 cells. Antibody content in the culture supernatant was determined by a radial-immunodiffusion assay using rabbit anti-mouse IgG antibodies in the immobile phase and mouse IgG (the monoclonal antibody) as the antigen in the mobile phase. This method was found to be more reproducible and reliable compared with an ELISA method. Cells were adapted to grow in an inexpensive, low protein content medium based on Dulbecco's Modified Eagle Medium (DMEM) supplemented with 0.25% Primatone RL, 0.01% Pluronic polyol F-68 and fetal bovine serum as low as 1%. Doubling time for the cells averaged 24 hrs, and final yields reached 2 X 10(6) cells per ml. The hybridoma cells were grown in the newly developed medium in 3 liter fermentors. Monoclonal antibody was produced during the early growth phase (3 days), however, most of the antibody was produced during a later growth phase (3-10 days) when 30 to 90% of the cells were dead. Final antibody yields were estimated to be 100-200 micrograms/ml. A low level of dissolved oxygen (25% air saturation) in the culture was found to increase the amount of antibody produced as compared with cells propagated at 60% air saturation (the optimal level for cell propagation) since the cells were kept alive for longer periods at the lower dissolved oxygen concentration. Using a fed-batch propagation method we were able to keep cells alive for long periods (up to 1 month) at a concentration of about 1 X 10(6) cells per ml, and thus to increase further monoclonal antibody production. Yields of 300-400 micrograms/ml were obtained.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3930316

Source DB:  PubMed          Journal:  Dev Biol Stand        ISSN: 0301-5149


  7 in total

1.  Batch production and growth kinetics of hybridomas.

Authors:  O W Merten
Journal:  Cytotechnology       Date:  1988-02       Impact factor: 2.058

2.  Importance of culturing primary lymphocytes at physiological oxygen levels.

Authors:  Kondala R Atkuri; Leonard A Herzenberg; Anna-Kaisa Niemi; Tina Cowan; Leonore A Herzenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-05       Impact factor: 11.205

3.  A serum substitute for fed-batch culturing of hybridoma cells.

Authors:  Keisuke Shibuya; Ryoichi Haga; Masaru Namba
Journal:  Cytotechnology       Date:  2008-07-17       Impact factor: 2.058

4.  Development of optimal medium for production of commercially important monoclonal antibody 520C9 by hybridoma cell.

Authors:  Sucharita Sen; Pradip K Roychoudhury
Journal:  Cytotechnology       Date:  2012-07-19       Impact factor: 2.058

5.  Effects of dissolved oxygen levels and the role of extra- and intracellular amino acid concentrations upon the metabolism of mammalian cell lines during batch and continuous cultures.

Authors:  R Heidemann; D Lütkemeyer; H Büntemeyer; J Lehmann
Journal:  Cytotechnology       Date:  1998-05       Impact factor: 2.058

6.  Enhancing effect of mouse peritoneal exudate cells and their products on antibody productivity of hybridoma cells: application of in vivo factors to in vitro culture.

Authors:  T Mikami; F Makishima; E Suzuki
Journal:  Cytotechnology       Date:  1991-10       Impact factor: 2.058

7.  Enhancement of hybridoma formation, clonability and cell proliferation in a nanoparticle-doped aqueous environment.

Authors:  Natalie Gavrilov-Yusim; Ekaterina Hahiashvili; Marina Tashker; Victoria Yavelsky; Ohad Karnieli; Leslie Lobel
Journal:  BMC Biotechnol       Date:  2008-01-14       Impact factor: 2.563

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.